[1] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[2] JACOBSON RA,MUNDING E,HAYDEN DM,et al.Evolving clinical utility of liquid biopsy in gastrointestinal cancers［J］.Cancers(Basel),2019,11(8):1164.
[3] WU C,ZHANG J,LI H,et al.The potential of liquid biopsies in gastrointestinal cancer［J］.Clin Biochem,2020,84:1-12.
[4] SIRAVEGNA G,MUSSOLIN B,VENESIO T,et al.How liquid biopsies can change clinical practice in oncology［J］.Ann Oncol,2019,30(10):1580-1590.
[5] SONG Z,WU Y,YANG J,et al.Progress in the treatment of advanced gastric cancer［J］.Tumour Biol,2017,39(7):1010428317714626.
[6] ZHANG X,LI M,CHEN S,et al.Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality:A Meta-analysis and systematic review［J］.Gastroenterology,2018,155(2):347-354.
[7] MILLER KD,NOGUEIRA L,MARIOTTO AB,et al.Cancer treatment and survivorship statistics,2019［J］.CA Cancer J Clin,2019,69(5):363-385.
[8] SIEGEL RL,MILLER KD,GODING SAUER A,et al.Colorectal cancer statistics,2020［J］.CA Cancer J Clin,2020,70(3):145-164.
[9] SMITH RA,ANDREWS KS,BROOKS D,et al.Cancer screening in the United States,2018:A review of current American Cancer Society guidelines and current issues in cancer screening［J］.CA Cancer J Clin,2018,68(4):297-316.
[10]MANDEL P,METAIS P.Les acidesnucléiques du plasma sanguin chez l' homme［J］.C R Seances Soc Biol Fil,1948,142(3-4):241-243.
[11]LEON SA,SHAPIRO B,SKLAROFF DM,et al.Free DNA in the serum of cancer patients and the effect of therapy［J］.Cancer Res,1977,37(3):646-650.
[12]LO YM,CORBETTA N,CHAMBERLAIN PF,et al.Presence of fetal DNA in maternal plasma and serum［J］.Lancet,1997,350(9076):485-487.
[13]STROUN M,ANKER P,MAURICE P,et al.Neoplastic characteristics of the DNA found in the plasma of cancer patients［J］.Oncology,1989,46(5):318-322.
[14]SORENSON GD,PRIBISH DM,VALONE FH,et al.Soluble normal and mutated DNA sequences from single-copy genes in human blood［J］.Cancer Epidemiol Biomarkers Prev,1994,3(1):67-71.
[15] ALIX-PANABIERES C,PANTEL K.Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy［J］.Cancer Discov,2016,6(5):479-491.
[16] PENG M,CHEN C,HULBERT A,et al.Non-blood circulating tumor DNA detection in cancer［J］.Oncotarget,2017,8(40):69162-69173.
[17] GORGANNEZHAD L,UMER M,ISLAM MN,et al.Circulating tumor DNA and liquid biopsy:opportunities,challenges,and recent advances in detection technologies［J］.Lab Chip,2018,18(8):1174-1196.
[18] ELAZEZY M,JOOSSE SA.Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management［J］.Comput Struct Biotechnol J,2018,16:370-378.
[19] WAN JCM,MASSIE C,GARCIA-CORBACHO J,et al.Liquid biopsies come of age:towards implementation of circulating tumour DNA［J］.Nat Rev Cancer,2017,17(4):223-238.
[20] CHAKRABARTI S,XIE H,URRUTIA R,et al.The promise of circulating tumor DNA(ctDNA) in the management of early-stage colon cancer:A critical review［J］.Cancers(Basel),2020,12(10):2808.
[21] CORCORAN RB,CHABNER BA.Application of cell-free DNA analysis to cancer treatment［J］.N Engl J Med,2018,379(18):1754-1765.
[22] GARCIA-FONCILLAS J,ALBA E,ARANDA E,et al.Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients:an expert taskforce review［J］.Ann Oncol,2017,28(12):2943-2949.
[23] ZHAO H,CHEN KZ,HUI BG,et al.Role of circulating tumor DNA in the management of early-stage lung cancer［J］.Thorac Cancer,2018,9(5):509-515.
[24] PARK JL,KIM HJ,CHOI BY,et al.Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients［J］.Oncol Lett,2012,3(4):921-926.
[25] KIM K,SHIN DG,PARK MK,et al.Circulating cell-free DNA as a promising biomarker in patients with gastric cancer:diagnostic validity and significant reduction of cfDNA after surgical resection［J］.Ann Surg Treat Res,2014,86(3):136-142.
[26] QIAN C,JU S,QI J,et al.Alu-based cell-free DNA:a novel biomarker for screening of gastric cancer［J］.Oncotarget,2016,8(33):54037-54045.
[27] GAO Y,ZHANG K,XI H,et al.Diagnostic and prognostic value of circulating tumor DNA in gastric cancer:a meta-analysis［J］.Oncotarget,2017,8(4):6330-6340.
[28] YANG YC,WANG D,JIN L,et al.Circulating tumor DNA detectable in early and late-stage colorectal cancer patients［J］.Biosci Rep,2018,38(4):BSR20180322.
[29] LAUGSAND EA,BRENNE SS,SKORPEN F.DNA methylation markers detected in blood,stool,urine,and tissue in colorectal cancer:a systematic review of paired samples［J］.Int J Colorectal Dis,2021,36:239-251.
[30] CHURCH TR,WANDELL M,LOFTON-DAY C,et al.Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer［J］.Gut,2014,63(2):317-325.
[31] NIAN J,SUN X,MING S,et al.Diagnostic accuracy of methylated SEPT9 for blood-based colorectal cancer detection:A systematic review and Meta-analysis［J］.Clin Transl Gastroenterol,2017,8(1):e216.
[32] SONG L,JIA J,PENG X,et al.The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests:A meta-analysis［J］.Sci Rep,2017,7(1):3032.
[33]LOOMANS-KROPP HA,SONG Y,GALA M,et al.Methylated Septin9(mSEPT9):A promising blood-based biomarker for the detection and screening of early-onset colorectal cancer［J］.Cancer Res Commun,2022,2(2):90-98.
[34] OTERO-ESTEVEZ O,GALLARDO-GOMEZ M,CADENA MP,et al.Value of serum NEUROG1 methylation for the detection of advanced adenomas and colorectal cancer［J］.Diagnostics(Basel),2020,10(7):437.
[35] SUEHIRO Y,HASHIMOTO S,HIGAKI S,et al.Blood free-circulating DNA testing by highly sensitive methylation assay to diagnose colorectal neoplasias［J］.Oncotarget,2018,9(24):16974-16987.
[36]LI D,ZHANG L,FU J,et al.SCTR hypermethylation is a diagnostic biomarker in colorectal cancer［J］.Cancer Sci,2020,111(12):4558-4566.
[37]BRENNE SS,MADSEN PH,PEDERSEN IS,et al.Colorectal cancer detected by liquid biopsy 2 years prior to clinical diagnosis in the HUNT study［J］.Br J Cancer,2023 Sep,129(5):861-868.
[38] GUO L,HUANG C,JI QJ.Aberrant promoter hypermethylation of p16,survivin,and retinoblastoma in gastric cancer［J］.Bratisl Lek Listy,2017,118(3):164-168.
[39] PIMSON C,EKALAKSANANAN T,PIENTONG C,et al.Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer［J］.PeerJ,2016,4:e2112.
[40] LIN Z,LUO M,CHEN X,et al.Combined detection of plasma ZIC1,HOXD10 and RUNX3 methylation is a promising strategy for early detection of gastric cancer and precancerous lesions［J］.J Cancer,2017,8(6):1038-1044.
[41] REN J,LU P,ZHOU X,et al.Genome-scale methylation analysis of circulating cell-free DNA in gastric cancer patients［J］.Clin Chem,2022,68(2):354-364.
[42] LI W,ZHANG X,LU X,et al.5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers［J］.Cell Res,2017,27(10):1243-1257.
[43] KOPRESKI MS,BENKO FA,BORYS DJ,et al.Somatic mutation screening:identification of individuals harboring K-ras mutations with the use of plasma DNA［J］.J Natl Cancer Inst,2000,92(11):918-923.
[44] THIERRY AR,MOULIERE F,EL MESSAOUDI S,et al.Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA［J］.Nat Med,2014,20(4):430-435.
[45] LYU N,RAJENDRAN VK,DIEFENBACH RJ,et al.Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay［J］.Nanotheranostics,2020,4(4):224-232.
[46] SHODA K,ICHIKAWA D,FUJITA Y,et al.Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer［J］.Gastric Cancer,2017,20(1):126-135.
[47]GRENDA A,WOJAS-KRAWCZYK K,SKOCZYLAS T,et al.HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery［J］.BMC Gastroenterol,2020,20(1):382.
[48] SCHWARZENBACH H,HOON DS,PANTEL K.Cell-free nucleic acids as biomarkers in cancer patients［J］.Nat Rev Cancer,2011,11(6):426-437.
[49] ABBOSH C,SWANTON C,BIRKBAK NJ.Clonal haematopoiesis:a source of biological noise in cell-free DNA analyses［J］.Ann Oncol,2019,30(3):358-359.
[50] MERKER JD,OXNARD GR,COMPTON C,et al.Circulating tumor DNA analysis in patients with cancer:American Society of Clinical Oncology and College of American Pathologists Joint Review［J］.J Clin Oncol,2018,36(16):1631-1641.
[51] SHAHJEHAN F,KAMATHAM S,KASI PM.Role of circulating tumor DNA in gastrointestinal cancers:Update from abstracts and sessions at ASCO 2018［J］.Front Oncol,2019,9:358.
[52]YOUNG GP,SYMONDS EL,NIELSEN HJ,etal.Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4,IKZF1 and BCAT1 for blood-based detection of colorectal cancer［J］.Clin Epigenetics,2021,13(1):14.
[53]WU X,ZHANG Y,HU T,et al.A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer［J］.Mol Oncol,2021,15(10):2702-2714.
[54]CHO NY,PARK JW,WEN X,etal.Blood-based detection of colorectal cancer using cancer-specific DNA methylation markers［J］.Diagnostics(Basel),2020,11(1):51.
[55]KANDIMALLA R,XU J,LINK A,et al.EpiPanGI Dx:A cell-free DNA methylation fingerprint for the early detection of gastrointestinal cancers［J］.Clin Cancer Res,2021,27(22):6135-6144.
[56]COHEN JD,LI L,WANG Y,et al.Detection and localization of surgically resectable cancers with a multi-analyte blood test［J］.Science,2018,359(6378):926-930.
[57]MATHIOS D,JOHANSEN JS,CRISTIANO S,et al.Detection and characterization of lung cancer using cell-free DNA fragmentomes［J］.Nat Commun,2021,12(1):5060.